A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, When Administered to Healthy Infants 6-8 Months Old.

Trial Profile

A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, When Administered to Healthy Infants 6-8 Months Old.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2015

At a glance

  • Drugs Meningococcal vaccine group B (Primary) ; Meningococcal vaccine group B OMV Novartis (Primary) ; Aluminium hydroxide
  • Indications Meningococcal group B infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 10 Sep 2008 Results have been reported by Novartis.
    • 10 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by Novartis.
    • 28 Aug 2007 Status changed from initiated to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top